Since it measures the total amount of circulating DNA (ctDNA) in a patient’s bloodstream using a simple blood draw, ctDNA liquid biopsy tests offers oncologists with an accurate, molecular, real-time cancer detection tool. It also helps to determine cancer staging and can help assess how aggressive the treatment regimen should be.
The company's been positioning itself as a contender in the precision medicine game - helping physicians navigate cancer therapy by examining cancer biomarkers in blood.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Celgene just made an equity investment Bay Area-based Sequenta, a biotech that’s developing a minimal residual disease test for blood cancer. The startup’s ClonoSight platform senses the remaining cancerous cells in a person’s blood stream after they’ve received radiation, surgery or chemotherapy – indicating whether or not a treatment has been successful, the company said. It […]
With a simple blood test, Epic Sciences can help physicians monitor the condition and severity of a cancer patient’s cancer by analyzing the intricacies of his or her circulating tumor cells. The San Diego company just raised $30 million in a Series C round to commercialize what CEO Murali Prahalad calls its “no cell left behind” diagnostic […]